Catherine Miller

Statistics

Publications

Citations

669

H-Index

Active since

1940

Affiliations

Biogen (United States)(Current)

St. Josef-Hospital

Biogen (United Kingdom)

University of Washington Medical Center

Washington University in St. Louis

Catherine Miller is an author at Biogen (United States) specializing in multiple sclerosis therapy, fumarate therapy, and relapsing-remitting multiple sclerosis treatment.

Publications per year

1940–2022

Publications

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

Robert T. Naismith, Annette Wundes, Tjalf Ziemssen et al. · CNS Drugs · 2020 · 130 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Effect of dimethyl fumarate on lymphocytes in RRMS

Devangi Mehta, Catherine Miller, Douglas L. Arnold et al. · Neurology · 2019 · 81 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results

Ralf Gold, Douglas L. Arnold, Amit Bar‐Or et al. · Multiple Sclerosis Journal · 2021 · 75 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +16

THE PRODUCTION OF SHOCK BY THE PROLONGED CONTINUOUS INJECTION OF ADRENALIN IN UNANESTHETIZED DOGS

N. E. Freeman, H. T. Freedman, Catherine Miller · American Journal of Physiology-Legacy Content · 1940 · 66 citations

Veterinary Medicine, Veterinary Pharmacology, Veterinary Physiology +5

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Robert T. Naismith, Jerry S. Wolinsky, Annette Wundes et al. · Multiple Sclerosis Journal · 2019 · 64 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

1–5 of 13